Bibliometric Analysis of Global Scientific Research on Economic Evaluation of Anticancer Agents

doi:10.19803/j.1672-8629.2021.08.08

Abstract

Abstract: Objective To conduct bibliometric analysis of pharmacoeconomic evaluation of anticancer agents. Methods Related literature and information were retrieved from Web of Science from inception to December 31, 2020. VosViewer software and Excel were used to analyze the trends relating to the volume of articles published in this field, country/regional contribution, contribution of research institutions, contribution of scholars, funds and hotspots of research. Results A total of 550 articles were included in the analysis. The overall number of published papers in this field continued upwards, especially in the past five years. The number of papers on anti-tumor pharmacoeconomics published in China was gradually leading the world. Drugs for non-small cell lung cancer (NSCLC) and new anticancer agents have become priorities of research in recent years. Conclusion The research on pharmacoeconomic evaluation of anticancer agents is fast-developing globally with the change of disease spectra and the acceleration of new drug research. With the implementation of policies on negotiations about national medical insurance drugs, the related research in China will gain momentum.

Key words: anticancer agents, pharmacoeconomic evaluation, bibliometric

CLC Number:

R956 R-056

CAO Zhaoliu, ZHANG Wei, QIAO Yang, MA Yuhao, HAN Feng, LI Xin. Bibliometric Analysis of Global Scientific Research on Economic Evaluation of Anticancer Agents[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 737-742.

References

[1] Wilson A, Cohen J.Patient access to new cancer drugs in the United States and Australia[J]. Value in Health, 2011, 14(6): 944-952.
[2] Kantarjian HM, Fojo T, Mathisen M, et al.Cancer drugs in the United States: Justum Pretium—the just price[J]. Journal of Clinical Oncology, 2013, 31(28): 3600.
[3] Robinson JC, Howell S.Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use[J]. Health Affairs, 2014, 33(10): 1745-1750.
[4] Cunningham PJ.The share of people with high medical costs increased prior to implementation of the affordable care act[J]. Health Affairs, 2015, 34(1): 117-124.
[5] Doshi JA, Li P, Pettit AR, et al.Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents[J]. J Clin Oncol, 2018, 36(5): 476-482.
[6] Carrera PM, Kantarjian HM, Blinder VS.The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment[J]. CA Cancer J Clin, 2018, 68(2): 153-165.
[7] Chen XZ, Jiang K, Hu JK, et al.Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China[J]. World Journal of Gastroenterology, 2008, 14(17):2715-2722.
[8] Crathorne L, Huxley N, Haasova M, et al.The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model[J]. Health Technol Assess, 2016, 20(13): 1-588.
[9] Lazzaro C, Barone C, Caprioni F, et al.An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study[J]. Expert Rev Pharmacoecon Outcomes Res, 2018, 18(4): 435-446.
[10] Hirsh V, Singh J.Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness[J]. Am J Health Syst Pharm, 2020, 77(18): 1466-1476.
[11] Maximiano S, Magalhães P, Guerreiro MP, et al.Trastuzumab in the treatment of breast cancer[J]. Bio Drugs, 2016, 30(2): 75-86.
[12] Mármol I, Sánchez-de-Diego C, Pradilla DA, et al. Colore-ctal carcinoma: a general overview and future perspectives in colorectal cancer[J]. Int J Mol Sci, 2017, 18(1): 197.
[13] Van Cutsem E, Köhne CH, Hitre E, et al.Cetuximab and chemot-herapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14): 1408-1417.
[14] Yoneda K, Imanishi N, Ichiki Y, et al.Treatment of non-small cell lung cancer with EGFR-mutations[J]. J Uoeh, 2019, 41(2): 153-163.
[15] Ahn MJ, Sun JM, Lee SH, et al.Egfr tki combination with immunotherapy in non-small cell lung cancer[J]. Expert Opin Drug Saf, 2017, 16(4): 465-469.
[16] HHerbst RS, Garon EB, Kim DW, et al.Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study[J]. Clin Oncol, 2020, 38(14): 1580-1590.